跳到主要內容區塊
定位點

Characteristics and Risk Factors Associated with Hepatitis C Virus Re-treatment in Taiwan (2017–2025)

發布單位:發布單位:癌症防治組

  • 點閱次數:點閱次數:652
  • 更新日期:更新日期:2026/09/30
  • 發布日期:發布日期:2026/09/30

Authors:

 Luo YX1, Hsu SM1, Chen HC1, Liu CL1, Ho TY1, Cheng KP1, Lin SH1, Wang PH2, Hsu TH2, Hsieh PC2, Lin LJ3, Shen CF3

1Hepatitis B & C Prevention and Control Office, Health Promotion Administration, Ministry of Health and Welfare, Taipei, Taiwan. 2Cancer Prevention and Control Division, Health Promotion Administration, Ministry of Health and Welfare, Taipei, Taiwan. 3Health Promotion Administration, Ministry of Health and Welfare, Taipei, Taiwan.

 

Background:

Taiwan has implemented a nationwide program for direct-acting antivirals (DAAs) to achieve the elimination of Hepatitis C virus (HCV). Despite significant treatment success, a small proportion of patients require a second treatment course. Understanding the characteristics of this population is essential for ensuring the long-term sustainability and success of HCV elimination goals.

 

Objectives:

To characterize the demographic and clinical profiles of patients undergoing HCV re-treatment and to identify independent risk factors associated with receiving multiple treatment courses.

 

Methods:

This retrospective study utilized nationwide DAA treatment records from 2017 to 2025. We analyzed 180,175 patients treated with DAAs, comparing the characteristics of those receiving a single course with those requiring re-treatment (n=2,760). Risk factor analysis focused on high-risk populations, including people with HIV (PWH), individuals with a history of Opioid Substitution Therapy (OST), and patients with End-Stage Renal Disease (ESRD). Multivariable logistic regression was employed to calculate adjusted odds ratios (aOR), controlling for age, gender, and enrollment in chronic disease management programs.

 

Results:

Compared to the single-treatment group, the re-treatment cohort was significantly younger (mean age 58.2 vs. 65.8 years) and exhibited a higher proportion of males (72.9%). Within high-risk categories, the prevalence was markedly higher in the re-treatment group for PWH (27.6% vs. 0.8%) and OST history (34.4% vs. 7.8%). Multivariable analysis identified PWH (aOR 6.06, 95% CI 5.46–6.74) and OST history (aOR 3.52, 95% CI 3.19–3.89) as primary independent risk factors. A notable age gradient was observed, with younger age groups showing higher odds of re-treatment. Conversely, ESRD did not show a statistically significant independent association (aOR 1.11, p = 0.478). Clinical assessment attributed 46% of re-treatment cases to relapse or re-infection.

 

Conclusion:

While HCV re-treatment remains infrequent (1.5%), it is significantly associated with younger age, male gender, and behavioral risk factors such as PWH status and substance use history. The high proportion of relapse or re-infection underscores the necessity for targeted post-treatment monitoring and integrated behavioral interventions for high-risk populations to ensure the durability of HCV elimination efforts.

看完本篇主題後,您的感覺如何?